Related references
Note: Only part of the references are listed.Is autoimmunity the Achilles' heel of cancer immunotherapy?
Carl H. June et al.
NATURE MEDICINE (2017)
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
Morganna Freeman-Keller et al.
CLINICAL CANCER RESEARCH (2016)
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
Ajjai Alva et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
Rikke Andersen et al.
CLINICAL CANCER RESEARCH (2016)
High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome
S. Chow et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
Noha Abdel-Wahab et al.
PLOS ONE (2016)
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
Hansje-Eva Teulings et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The High-Dose Aldesleukin Select Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma
David F. McDermott et al.
CLINICAL CANCER RESEARCH (2015)
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Janice P. Dutcher et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
Francesco Torino et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto et al.
CLINICAL CANCER RESEARCH (2012)
Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
Laszlo G. Radvanyi et al.
CLINICAL CANCER RESEARCH (2012)
Autoimmunity associated with immunotherapy of cancer
Sally M. Amos et al.
BLOOD (2011)
Autoimmunity and treatment outcome in melanoma
Marna G. Bouwhuis et al.
CURRENT OPINION IN ONCOLOGY (2011)
High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma - A retrospective analysis of response and survival in patients treated in the Surgery Branch at the National Cancer Institute between 1986 and 2006
Jacob A. Klapper et al.
CANCER (2008)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cytotoxic T-Lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
JA Blansfield et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2
KA Chianese-Bullock et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
JC Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer
PG Fraenkel et al.
JOURNAL OF IMMUNOTHERAPY (2002)
Guidelines for the safe administration of high-dose interleukin-2
DJ Schwartzentruber
JOURNAL OF IMMUNOTHERAPY (2001)
Share Paper
